Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Price Breaks Above 200 Day Moving Average - Should You Sell?

Key Points

• Fresenius Medical Care’s stock rose above its 200-day moving average, reaching $23.13 and last trading near $23.11, up 2.1%.
• Analyst sentiment remains cautious: the consensus rating is “Reduce”, based on seven Hold and four Sell ratings, with an average price target of $23.42.
• The company exceeded quarterly expectations, reporting $0.66 in EPS versus $0.62 expected and $5.55 billion in revenue versus a $5.48 billion consensus estimate.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report)'s stock price passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $22.88 and traded as high as $23.13. Fresenius Medical Care AG & Co. KGaA shares last traded at $23.1050, with a volume of 1,361,082 shares traded.

Analyst Upgrades and Downgrades

FMS has been the topic of several recent research reports. Sanford C. Bernstein upped their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a "market perform" rating in a report on Thursday, August 6th. Berenberg Bank set a $24.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, September 29th. BNP Paribas Exane lowered shares of Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 price target on the stock. in a research report on Tuesday, July 28th. Zacks Research cut shares of Fresenius Medical Care AG & Co. KGaA from a "hold" rating to a "strong sell" rating in a research note on Thursday, October 15th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Seven investment analysts have rated the stock with a Hold rating and four have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Reduce" and an average target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Stock Up 2.1%

The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a market cap of $12.41 billion, a P/E ratio of 11.97, a price-to-earnings-growth ratio of 5.28 and a beta of 0.74. The stock's fifty day moving average is $22.41 and its two-hundred day moving average is $22.88.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. The firm had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.48 billion. As a group, research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.24 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 39.1% in the third quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company's stock worth $43,000 after purchasing an additional 538 shares during the last quarter. Advisors Preferred LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 6.1% during the 1st quarter. Advisors Preferred LLC now owns 10,226 shares of the company's stock valued at $231,000 after buying an additional 589 shares during the period. Allworth Financial LP boosted its position in Fresenius Medical Care AG & Co. KGaA by 31.5% during the 2nd quarter. Allworth Financial LP now owns 3,552 shares of the company's stock valued at $80,000 after buying an additional 850 shares during the period. Parallel Advisors LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 27.9% during the 1st quarter. Parallel Advisors LLC now owns 4,632 shares of the company's stock valued at $104,000 after buying an additional 1,011 shares during the period. Finally, Trek Financial LLC grew its holdings in Fresenius Medical Care AG & Co. KGaA by 9.2% in the 3rd quarter. Trek Financial LLC now owns 12,350 shares of the company's stock worth $276,000 after acquiring an additional 1,040 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company's stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.